Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Both men and women between 18 and 70 years.~* Patient with active lupus nephritis, previously treated with cyclophosphamide and mycophenolate (sodium or mofetil), who have not received rituximab in the previous year.~* Women in childbearing age must have a pregnancy test in serum or urine negative and should use a contraceptive method suitable since at least 14 days prior to their inclusion in the study and up to 6 months after the last dose of the medication of the test.~* Informed consent form signed.~Exclusion Criteria:~* Patients treated with rituximab in the previous years~* Active/sepsis serious infections~* Renal biopsy showing interstitial fibrosis and/or glomerular over 75%.~* Known neoplasia~* Heart failure with III/IV functional class~* Pregnancy~* Nursing~* Known anaphylaxis to the product~* History of hepatitis c~* History of tuberculosis~* Cardiovascular disease or uncontrolled hypertension~* Chronic hepatitis B~* Serious Cytopenia (granulocytes \< 500/mm3, further \< 10000/mm3)~* Immunodeficiency (CVI, immunoglobulins deficiency)~* Infection with HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (1 cycle) (Type: ACTIVE_COMPARATOR): 1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2
- Rituximab (2 cycles) (Type: EXPERIMENTAL): A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)

Based on this trial design, predict the completion outcome and termination type (if applicable).